title: [A case of advanced gastric cancer in which the serum HER2-ECD level could be used as a biomarker].
abstract: An 83-year-old woman was diagnosed as having advanced gastric cancer with multiple lymph node and hepatic metastases. Histopathological examination revealed that the tissue was human epidermal growth factor receptor 2(HER2)positive. The patient underwent gastrojejunostomy to improve stomach obstruction. Thereafter, S-1 and trastuzumab combination chemotherapy was administered as first-line treatment; irinotecan(CPT-11), cisplatin, and trastuzumab combination chemotherapy, as second-line treatment; and docetaxel plus trastuzumab combination chemotherapy, as third-line treatment. Although both primary and metastatic lesions decreased in size temporarily, their size increased again, and the patient died 1 year and 7 months later. The level of serum HER2-extracellular domain(ECD)was a valuable indicator of response to chemotherapy. Thus, serum HER2-ECD could be a useful biomarker for HER2-positive gastric cancer.
authors.affiliation: Dept. of Gastroenterologic Surgery, Kanazawa University.
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Terakawa
authors.forename: Katsunobu
authors.initials: K
authors.lastname: Oyama
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Watanabe
authors.forename: Tomoya
authors.initials: T
authors.lastname: Tsukada
authors.forename: Koichi
authors.initials: K
authors.lastname: Okamoto
authors.forename: Jun
authors.initials: J
authors.lastname: Kinoshita
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Furukawa
authors.forename: Isamu
authors.initials: I
authors.lastname: Makino
authors.forename: Keishi
authors.initials: K
authors.lastname: Nakamura
authors.forename: Hironori
authors.initials: H
authors.lastname: Hayashi
authors.forename: Masafumi
authors.initials: M
authors.lastname: Inokuchi
authors.forename: Hisatoshi
authors.initials: H
authors.lastname: Nakagawara
authors.forename: Tomoharu
authors.initials: T
authors.lastname: Miyashita
authors.forename: Hidehiro
authors.initials: H
authors.lastname: Tajima
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takamura
authors.forename: Itasu
authors.initials: I
authors.lastname: Ninomiya
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Kitagawa
authors.forename: Sachio
authors.initials: S
authors.lastname: Fushida
authors.forename: Takashi
authors.initials: T
authors.lastname: Fujimura
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Ohta
mesh_terms: D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D005110:Extracellular Space; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood* / Q000737:chemistry; D013274:Stomach Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human